New FDA-Approved COPD Drug Ensifentrine Shows Promise in Major Clinical Trials
Ensifentrine (Ohtuvayre) represents the first new FDA-approved COPD medication in over a decade, offering hope for millions with chronic obstructive pulmonary disease. This nebulized drug works through a novel dual mechanism, inhibiting both phosphodiesterase 3 and 4 enzymes to simultaneously relax airway smooth muscle and reduce inflammation. The ENHANCE clinical trials involving 1,400 patients demonstrated statistically significant improvements in lung function (87-94ml FEV1 increase) and reduced exacerbation rates when added to standard therapy. Approved for moderate to severe COPD patients with 30-70% predicted lung function, the medication is taken twice daily via nebulizer. While well-tolerated with similar side effects to placebo, the drug costs approximately $3,000 wholesale, raising questions about insurance coverage and accessibility.